Business Context and Reporting Period
Company: SelectQuote, Inc. (SLQT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended June 30, 2025
Business Overview: SelectQuote is a technology-enabled, direct-to-consumer (DTC) distribution platform for insurance policies and healthcare services. The company operates three reportable segments: Senior (Medicare Advantage and Supplement), Healthcare Services (SelectRx pharmacy, Healthcare Select, and SelectPatient Management), and Life (Term and Final Expense). The Auto & Home segment is now reported under "All Other" as it no longer meets quantitative thresholds for separate reporting. The company leverages proprietary AI and machine learning to optimize lead acquisition and agent routing.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
|---|---|---|---|
| Total Revenue | $1,526,594 | $1,321,776 | $1,002,848 |
| Net Income (Loss) | $47,580 | $(34,125) | $(58,544) |
| Net Income Attributable to Common Shareholders | $25,032 | $(34,125) | $(58,544) |
| Operating Income | $68,499 | $64,550 | $11,583 |
| Adjusted Segment EBITDA | $213,727 | $194,729 | $155,381 |
| Operating Cash Flow | $(11,666) | $15,236 | $(19,377) |
| Total Debt Obligations | $385,112 | $683,334 | N/A |
| Cash, Cash Equivalents, and Restricted Cash | $37,066 | $42,690 | $83,156 |
Revenue Composition (Fiscal 2025)
- Pharmacy (Healthcare Services): $728.8 million (48% of total revenue), up 57% year-over-year.
- Commissions and Other Services: $797.8 million (52% of total revenue), down 7% year-over-year.
- Senior Segment Revenue: $600.4 million (down 8% YoY).
- Life Segment Revenue: $173.0 million (up 10% YoY).
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to net profitability in Fiscal 2025 ($47.6 million) compared to a net loss of $34.1 million in Fiscal 2024. This was driven by a $59.5 million non-cash gain from the change in fair value of warrant liabilities and improved operating margins in the Healthcare Services segment.
- Healthcare Services Growth: SelectRx pharmacy revenue surged 57% to $728.8 million, driven by a 31% increase in active members (108,018 as of June 30, 2025). Adjusted EBITDA for this segment improved significantly to $25.4 million from $7.8 million.
- Senior Segment Decline: Senior revenue decreased 8% due to a 4% drop in approved policies and a 3% decrease in Lifetime Value (LTV) per approved policy. This was attributed to carrier mix changes and plan terminations affecting persistency.
- Debt Reduction: Total debt obligations decreased by approximately $298 million (from $683.3 million to $385.1 million). This reduction was achieved through a $350 million Senior Non-Convertible Preferred Stock transaction and a $100 million securitization transaction, proceeds of which were used to repay term loans.
- Impairment Charges: The company recorded a $4.2 million non-cash impairment charge related to the write-off of intangible assets from the InsideResponse acquisition.
Guidance, Outlook, and Risks
Management Commentary and Strategy
Management continues to prioritize the expansion of the Healthcare Services platform (SelectRx and SelectPatient Management) as a higher-growth opportunity compared to the traditional insurance distribution business. The company is de-emphasizing production in the Auto & Home segment. Strategic focus remains on maximizing the Lifetime Value (LTV) of commissions through improved retention and cross-selling.
Key Risks and Contingencies
- Regulatory and Legal: The company is subject to a qui tam action (DOJ Action) alleging violations of the False Claims Act regarding sales and marketing practices. The company denies the allegations and is defending vigorously. Additionally, the company faces ongoing securities class action litigation regarding prior disclosures.
- Carrier Concentration: Revenue is heavily concentrated among a few carriers. For Fiscal 2025, UnitedHealthcare (37%), Aetna (15%), and Humana (11%) accounted for 63% of total revenue. Termination of these relationships would materially harm the business.
- Seasonality: A significant portion of revenue (approx. 31% in Fiscal 2025) is generated during the second quarter due to the Medicare Annual Enrollment Period (AEP).
- Debt Covenants: The company must maintain compliance with financial covenants under its Senior Secured Credit Facility and Indenture. Management believes it will remain compliant for the next 12 months.
- Warrant Liability Volatility: Net income was significantly impacted by a $59.5 million gain from the change in fair value of warrant liabilities. Future fluctuations in stock price could materially affect earnings.
Investor Verification Checklist
- Warrant Liability Impact: Verify the sustainability of net income by excluding the $59.5 million non-cash gain from warrant fair value changes to assess core operational profitability.
- Pharmacy Margins: Monitor the gross margin of the SelectRx pharmacy business, as rapid growth in prescription volume (up 47% in prescriptions per day) must be balanced against rising medication costs and reimbursement rate pressures.
- Senior Segment Persistency: Review the "Lifetime Value of Commissions" assumptions and actual renewal rates for Medicare Advantage policies, as a 3% decline in LTV was noted due to persistency deterioration.
- Legal Proceedings: Track the status of the DOJ False Claims Act action and the pending securities class action appeal, as unfavorable outcomes could result in significant penalties or operational restrictions.
- Debt Structure: Confirm the terms and dividend obligations of the new $350 million Senior Non-Convertible Preferred Stock (14.5% annual dividend rate) and its impact on future cash flows.